Last reviewed · How we verify
Docetaxel (D)
Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.
At a glance
| Generic name | Docetaxel (D) |
|---|---|
| Also known as | Taxotere |
| Sponsor | BeyondSpring Pharmaceuticals Inc. |
| Drug class | Taxane; microtubule stabilizer |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Docetaxel is a taxane that binds to the β-tubulin subunit of microtubules and prevents their disassembly, leading to stabilization of the microtubule structure. This disrupts normal cell division by preventing the formation of the mitotic spindle, causing cells to arrest in the G2/M phase of the cell cycle and undergo apoptosis. It is effective against a broad range of solid tumors with high mitotic activity.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Prostate cancer
- Gastric adenocarcinoma
- Head and neck cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Alopecia
- Nausea/vomiting
- Diarrhea
- Mucositis
- Hypersensitivity reactions
- Fluid retention
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (PHASE2)
- A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (PHASE1)
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (PHASE1, PHASE2)
- PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PHASE2)
- A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (PHASE3)
- Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer (PHASE2)
- A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel (D) CI brief — competitive landscape report
- Docetaxel (D) updates RSS · CI watch RSS
- BeyondSpring Pharmaceuticals Inc. portfolio CI